Smoldering acute myelogenous leukemia in the elderly

Area of Science:

• Hematology
• Oncology
• Geriatrics

Background:

• Elderly patients with acute myeloid leukemia (AML) often have poor prognoses.
• Treatment decisions for older AML patients require careful consideration of potential benefits and risks.

Observation:

• Six elderly AML patients receiving only supportive care survived for extended periods (13.2-98 months).
• These patients had distinct clinical and laboratory features compared to rapidly progressing AML cases.
• Features included better performance status, lower white blood cell and blast counts, and higher platelet counts.

Findings:

• These long-term survivors were all AML2 FAB subtype, with some de novo and some post-myelodysplastic syndrome (MDS).
• Cytogenetic analysis revealed normal karyotypes in available cases.
• In vitro leukemic cell growth was absent or reduced in clonogenic assays.

Implications:

• Identifying specific characteristics of smoldering AML in the elderly is crucial for understanding disease pathophysiology.
• This knowledge can aid in optimizing treatment strategies and timing for elderly AML patients.
• Distinguishing smoldering AML may prevent unnecessary or overly aggressive treatments in select elderly individuals.